Rozanolixizumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Rozanolixizumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
24
Registered trials
37
Result records
17
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Rozanolixizumab can convert its Monoclonal antibody profile and FcRn biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Rozanolixizumab (query alias: rozanolixizumab) |
|---|---|
| Modality / target | Monoclonal antibody; FcRn; FcRn antagonists, Immunomodulators |
| Highest global status | Approved |
| Originator | UCB SA |
| Active developers | UCB Biopharma SRL, UCB SA, UCB Pharma SA |
The MCP disease footprint includes Thrombocytopenia, Myasthenia Gravis, Myasthenia Gravis, Ocular. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07246564 | Phase 4 | Recruiting | 40 | Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment Cycle |
| NCT07463521 | Phase 3 | Recruiting | 120 | Change from Baseline at Day 43 in (Myasthenia Gravis Impairment Index) MGII ocular score (Patient-Reported Outcome (PRO) part) |
| NCT07465289 | Phase 3 | Not yet recruiting | 100 | Incidence of treatment-emergent adverse events (TEAEs) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
An Open-Label, Single-Dose Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
Phase 1; n=15; evaluation: not stated. Reported fields: Predose (Day 1)(Geometric Mean) = NA micrograms per milliter (ug/mL) (Geometric Coefficient of Variation, NA); -; -
Switching to rozanolixizumab from efgartigimod: Real-world outcomes in patients with generalized myasthenia gravis in the United States
Not Applicable; n=26; evaluation: Positive. Reported fields: HCRU(≥1 MG exacerbation) = 69.2 %
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Phase 3; n=200; evaluation: Positive. Reported fields: MGII PASS(≤ 10 points) = 39.2 % ; MGII PASS(≤ 10 points) = 30.8 % ; MGII PASS(≤ 10 points) = 7.7 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Rozanolixizumab addresses Thrombocytopenia, Myasthenia Gravis, Myasthenia Gravis, Ocular. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 17 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: FcRn records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-11-03 | Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases | Preclinical | US$8.0M upfront; US$736.0M milestones |
| 2022-10-27 | FUJIFILM Diosynth Biotechnologies Enters Into an Agreement with Argenx to Manufacture Efgartigimod, a monoclonal antibody (mAb) for the Treatment of Severe Autoimmune Diseases | Approved | Financial terms not disclosed |
| 2022-10-10 | CSPC NBP Pharmaceutical partners with Harbour BioMed to develop and market HBM-9161 for autoimmune diseases in Greater China. | Phase 3 | US$21.1M upfront; US$121.3M milestones; US$142.5M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
